

Article

Subscriber access provided by University of Sussex Library

Indium-mediated Intramolecular Reaction of N-(2iodobenzoyl)-Azabenzonorbornadienes: A General Access to Dihydroben-zo[c]phenanthridinones

Yang Liu, Na Liu, Dong-Wei Sun, Xue-Wen Hua, Ya-Juan Li, Kang Lei, and Xiao-Hua Xu J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.6b00839 • Publication Date (Web): 31 May 2016 Downloaded from http://pubs.acs.org on May 31, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Indium-mediated Intramolecular Reaction of *N*-(2-iodobenzoyl)-Azabenzonorbornadienes: A General Access to Dihydrobenzo[*c*]phenanthridinones

Yang Liu, Na Liu, Dong-Wei Sun, Xue-Wen Hua, Ya-Juan Li, Kang Lei* and Xiao-Hua Xu*

State Key Laboratory and Institute of Elemento-organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin 300071, China



ligand free, base free, easy operation 20 examples 58%-91%

ABSTRACT: An efficient synthesis of dihydrobenzo[*c*]phenanthridinones was achieved through utilizing an indium(0)-mediated intramolecular cyclization reaction under ligand- and base-free conditions. A variety of functional groups were tolerated in the present protocol.

INTRODUCTION

Benzo[c]phenanthridines are an important group of naturally occurring alkaloids that widely exist in *Papaveraceae* and *Putaceae* plants.¹ Many members of this family (Figure 1), such as chelidonine, chelamidine, chelamine, homochelidonine, sanguinarine, and nitidine, often possess various interesting biological activities,² which has made them attractive targets for chemical and biological community.^{3–8} Related the aromatic congeners, synthesis of the partial unsaturated dihydrobenzo[c]phenanthridine alkaloids of this family still remains challenging due to the existence of two contiguous chiral bridge carbon atoms. Among the previously described methods for them, much attention has been paid to the ring-opening reaction of azabenzonorbornadienes resulting in the benzo[c]phenanthridine skeletons. In particular, Lautens et al. reported a highly efficient synthesis of natural dihydrobenzo[c]phenanthridines through using Pd-catalyzed ring-opening reactions of azabenzonorbornadienes with an aryl boronic acid as the key step.^{4, 5} Our group also developed an efficient method to construct dihydrobenzo[c]phenanthridinones through the ring-

opening reaction of azabenzonorbornadienes with methyl o-iodobenzoates, which was successfully applied to the total synthesis of five natural benzo[c]phenanthridines.^{6–8} (Scheme 1) All these reports involved an elaborated Pd catalytic system and there were few studies on the intramolecular cyclization reaction of azabenzonorbornadienes. From a practical perspective, the ring-opening reaction of azabenzonorbornadienes with a cheaper metal, simple reaction system is highly desirable.

Figure 1. Naturally occuring benzo[c]phenanthridine alkaloids



As a relatively inexpensive metal, Indium exhibits a low heterophilicity in many organic reactions and thus oxygen- and nitrogen-containing functional groups are usually tolerated by these organoindium reagents. In the past few decades, indium-mediated organic reactions have elicited considerable attention. Most synthetically useful indium-mediated reactions are mainly limited to the Ferrier-type alkynylation reactions and allyl alkylation of carbonyl compounds and imine derivatives,^{9,10} while few reports involved the indium-mediated ring-opening reaction of azabicyclic olefins.^{11,12} Cheng and co-workers have reported a Pd-catalyzed ringopening process of azabicyclic olefins with organic halides via an abnormal Heck-type reaction.¹³ Wang et al. reported an indium(III)-catalyzed Heck reaction and suggested that the organoindium intermediate, generated in situ from the reaction of phenyl iodide and indium salt, could easily react with styrene to provide the Heck reaction compound.¹⁴ Recently, we also turned our interest to the indium-mediated Heck-type reactions. To this end, we envisaged that the ring-opening reaction of azabenzonorbornadienes could be promoted by an indium reagent.





Our continuous efforts on synthesis of benzo[c] phenanthridines^{6–8} in combination with indium chemistry^{15,16} has resulted in development of a few new approaches to dihydrobenzo[c] phenanthridinones through a Pd-catalyzed intermolecular cascade reaction (Scheme 1). As parts of our ongoing project about indium chemistry, we herein report a new methodology for synthesis of dihydrobenzo[c] phenanthridines based on an intramolecular cyclization reaction of *N*-(2-iodobenzoyl)-azabenzonorbornadienes.

RESULTS AND DISCUSSION

As we know, an organoindium reagent can be formed by treatment of aryl iodide with the indium(0) metal.¹⁷ Thus, the substrates bearing an iodide group, *N*-(2-iodobenzoyl)-azabenzonorbornadiene **1a**, were prepared smoothly according to the previously reported methods.¹⁸ With substrates **1a** in hand, we subsequently examine its behavior with indium metal. In our initial attempts, the reaction of **1a** with 1.5 equiv indium in the presence of 2.0 equiv LiCl at 110 °C did not produce any desired products **2a** (entry 1, Table 1). To our delight, when LiCl was removed from the reaction system, the reaction produced **2a** in 52 % yield with incomplete conversion of the starting material (entry 2, Table 1). Further studies have demonstrated that DMF proved to be the optimal solvent for this process (entries 8 and 9, Table 1), while other solvents such as toluene, dioxane, THF, DME, and methanol failed to provide the desired products (entries 11-14, Table 1). The molar quantity of the indium metal also significantly influenced the reaction efficacy. The highest yield was obtained with a 2.5 equivalent of In(0) metal (entry 8, Table 1). Finally, the *cis*-stereochemistry of pruduct **2a** was confirmed by X-ray diffraction crystallographic analysis (see the Supporting Information).¹⁹

 Table 1. Intramolecular Reaction of Compound 1a^a



Entry	In (Equiv.)	Solvent	Temp. (°C)	Yield (%) ^b
1 ^c	1.5	DMF	110	0
2	1.5	DMF	110	52
3	1.5	DMF	120	49
4	1.5	DMF	130	51
5	1.5	DMF	140	52
6	1.0	DMF	110	33
7	2.0	DMF	110	70
8	2.5	DMF	110	84
9	3.0	DMF	110	84
10^d	2.5	DMF	110	56
11	2.5	toluene	110	0
12	2.5	1,4-dioxane	110	0
13	2.5	THF	110	0
14	2.5	DME	110	0

15	2.5	DMSO	110	78
16	2.5	MeOH	110	21
17^e	2.5	DMF	110	67

^{*a*} Reaction conditions: **1a** (0.2 mmol), In, solvent (2.5 mL), 20 h, under an argon atmosphere. ^{*b*} Isolated yield. ^{*c*} In·LiCl was used. ^{*d*} Reaction time:10 h. ^{*e*} 1 mmol of **1a** was used.

Next, using the abovementioned optimized reaction conditions, we examined the scope and limitations of this present protocol. The results are summarized in Table 2. A range of *N*-(2-iodobenzoyl)-azabenzonorbornadienes **1b**-**1p** with various substituents in the aromatic ring was examined. Fifteen dihydrobenzo[*c*]phenanthridinones **2b**-**2p** were successfully obtained under the optimal conditions with a yield of 58 to 91 % (entries 1 to 16, Table 2). Both the electron-donating and electron-withdrawing groups were tolerated in the present procedure. Related to the electronic properties in compounds **1**, the steric characters of the substrates significantly influenced the efficacy of the reactions. The substrates possessing a substituent adjacent to the iodide group generally gave a decreased yield (entries 2 to 4, Table 2). It is noteworthy that compounds 20 and 2p represent the mature precursors for naturally occurring alkaloids chelidonine and nitidine. Unfortunately, reactions with the corresponding aryl bromide and chloride did not yield the target benzo[*c*]phenanthridies (entries 17 and 18, Table 2).

 Table 2. Intramolecular Reaction of Compounds 1a-1r^a



The Journal of Organic Chemistry



^{*a*} Reaction conditions: 1 (0.2 mmol), In (0.5 mmol), DMF (2.5 mL), 110 °C, 20 h, under an argon atmosphere. ^{*b*} isolated yield.

To examine the generality of the present methodology, the chain-extending substrates N-(2-iodiophenylacetyl)azabenzonorbornadiene derivatives **3** and N-(2-iodiophenylpropionyl)-azabenzonorbornadiene **5** were also subject to the indiummediated cyclization process and the results are shown in Scheme 2. To our delight, under optimized reaction conditions the reactions of phenylacetic acid-derived subsrates **3a** and **3b** provided smoothly the desired products **4a** and **4b** in a yield 84 % and 91 %,

respectively. However, the 3-phenylpropanyl acid-derived N-(2-iodiophenylpropionyl)-azabenzonorbornadiene 5 proved to be not

an effective substrate.





Subsequently, regioselectivity of the present reaction was further studied (Scheme 3). For compounds **6a** and **6b** containing a methyl group in the bridgehead atom, two possible cyclization products might be afforded. Nevertheless, only a single regio-isomer dihydrobenzo[*c*]phenanthridinones **7a** and **7b** were obtained in 72 % and 63 % yield, respectively. Unexpectedly, compound **6c**, which incorporates a methyl group at the double bond, did not supply the desired phenanthridine derivative under the optimal reaction conditions. It was presumed that the presence of the methyl group on the C-C double bond of olefin possible hampered the coordination to the indium center generated in situ.

Scheme 3. Investigation of the regioselectivity



The Journal of Organic Chemistry

Based on the abovementioned results and previously reported work,^{13,14,17} a plausible mechanism for the synthesis of dihydrobenzo[*c*]phenanthridinones is putatively outlined in Scheme 4. At the outset, an organoindium immediate **8** was formed in situ. The subsequent intramolecular insertion reaction into carbon-carbon double bond of the olefin produced a cyclic intermediate **9**, which underwent a β -elimination/ring opening to give the full scaffold **10**. Finally, the protonation of **10** provided the benzophenanthridine **2a**.

Scheme 4. Plausible reaction mechanism



CONCLUSION

In conclusion, we have described an efficient In(0)-mediated intramolecular cyclization strategy for synthesis of dihydrobenzo[*c*]phenanthridinone derivatives from *N*-(2-iodobenzoyl)-azabenzonorbornadienes. This present methodology was demonstrated to have widely functional group tolerance and highly regioselectivity. Further investigation on the enantioselective synthesis of benzo[*c*]phenanthridinones utilizing the protocol is currently under development and will be reported in the future.

EXPERIMENT SECTON

Chemicals and solvents were purchased from commercial suppliers and used as received unless otherwise stated. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) were recorded with CDCl₃ or DMSO-d₆ as solvent. The chemical shifts are reported as δ values (ppm) relative to tetramethylsilane. HRMS spectra were recorded with a Q-TOF mass spectrometer, equipped with an ESI source. Melting points were determined with a melting point apparatus and are uncorrected.

General procedure for synthesis of substrates 1a to 1r, 3a, 3b and 5

Compounds 1a to 1r, 3a, 3b and 5 were synthesized according to the previous reported method.¹⁸

To *N*-Boc pyrrole (16.7 g, 100 mmol) in DME (40 mL) at 55 °C in a flame dried three-neck flask fitted with a reflux condenser and two addition funnels was simultaneously added a solution of anthranilic acid (13.8 g, 100 mmol) in DME (100 mL) and a separate solution of

isoamylnitrite (16.8 mL, 125 mmol) in DME (50 mL). The addition took about 45 minutes. The reaction was allowed to stir at 55 °C for 30 min until no further gas was evolved. The crude red solution was reduced in volume by rotovap distillation to approximately half the original volume. The reaction mixture was then partitioned between EtOAc and saturated K_2CO_3 and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated. The resulting dark brown oil was purified by column chromatography on silica gel (petroleum ether/ethyl acetate 20/1 v/v) to give *N*-Boc intermediate (13.85 g, 57%) as light yellow solid.

N-Boc intermediate (600 mg, 2.4 mmol) was dissolved in 10 mL DCM followed by the addition of Et₃N (0.4 mL) and heating to reflux. TMSI (0.4 mL, 2.6 mmol) was added dropwise over 5 min and the reaction was heated at reflux for an additional 15 minutes, after which time TLC analysis showed complete consumption of *N*-Boc intermediate. The reaction mixture was cooled to 0 °C then MeOH (0.1 mL, 3 mmol) was added dropwise. After 10 minutes at 0 °C, 2-iodobenzoyl chloride (954 mg, 3.6 mmol) was added and the reaction was allowed to warm to room temperature. The reaction was stirred at room temperature for an additional hour. Water (10 mL) and DCM was added until all precipitates dissolved. The organic and aqueous phases were separated and the aqueous phase was extracted twice with DCM. The organic fractions were combined, dried over Na_2SO_4 and concentrated. The resulting crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=10/1 v/v) to give compound **1a** (682 mg, 74 %) as a white solid.

The rest of substrates 1b to 1r, 3a, 3b and 5 were prepared by the similar procedure to 1a.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(2-iodophenyl)methanone (1a): light yellow solid, 600 mg, 74 %; m.p. 123–125 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.83 (dd, J = 7.9, 0.5 Hz, 1H), 7.36–7.32 (m, 2H), 7.17–7.05 (m, 4H), 7.02–6.92 (m, 3H), 6.09 (s, 1H), 5.07 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 163.9, 147.9, 147.8, 143.7, 142.8, 140.8, 139.7, 130.9, 128.1, 127.6, 125.4, 125.2, 121.5, 120.6, 92.2, 66.7, 63.0; HRMS (ESI): m/z calcd for C₁₇H₁₂INO [M+H]⁺374.0042, found 374.0042.

(3-Chloro-2-iodophenyl)(1,4-dihydro-1,4-epiminonaphthalen-9-yl)methanone (1b): light yellow solid, 664 mg, 68 %; m.p. 186–188 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.51 (dd, J = 8.0, 1.5 Hz, 1H), 7.39 (d, J = 6.6 Hz, 1H), 7.33 (t, J = 7.7 Hz, 1H), 7.22–7.12 (m, 2H), 7.05–6.97 (m, 4H), 6.13 (s, 1H), 5.08 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 161.8, 146.7, 146.6, 142.9, 142.5, 141.7, 139.1, 128.8, 128.5, 124.4, 124.2, 124.1, 120.5, 119.6, 95.7, 65.4, 61.9; HRMS (ESI): m/z calcd for C₁₇H₁₁ClINO [M+H]⁺ 407.9652, found 407.9645.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(3-fluoro-2-iodophenyl)methanone (1c): off white solid, 572 mg, 61 %; m.p. 183–185 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.40–7.33 (m, 2H), 7.21–7.08 (m, 3H), 7.07–6.97 (m, 3H), 6.95 (d, J = 7.4 Hz, 1H), 6.12 (s, 1H), 5.09 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 161.6 (d, J = 2.3 Hz), 160.9 (d, J = 247.0 Hz), 146.6 (d, J = 14.0 Hz), 142.6, 142.0, 141.6, 129.3, 129.2, 124.3 (d, J = 14.8 Hz), 122.1 (d, J = 3.5 Hz), 120.5, 119.6, 115.2 (d, J = 24.6 Hz), 79.6 (d, J = 27.4 Hz), 65.6, 61.9; HRMS (ESI): m/z calcd for C₁₇H₁₁FINO [M+H]⁺ 391.9948, found 391.9948.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(2-iodo-3-methylphenyl)methanone (1d): white solid, 669 mg, 72 %; m.p. 153–155 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.36 (d, J = 6.7 Hz, 1H), 7.28–7.22 (m, 2H), 7.15–7.11(m, 2H), 7.04–6.94 (m, 3H), 6.88 (s, 1H), 6.12 (s, 1H), 6

1H), 5.07 (s, 1H), 2.47 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ : 162.9, 146.9, 141.9, 141.8, 141.0, 129.2, 127.1, 124.3, 124.1, 123.6, 120.4, 119.5, 97.8, 65.5, 61.8, 27.9; HRMS (ESI): m/z calcd for C₁₈H₁₄INO [M+H]⁺ 388.0198, found 388.0197.

(4-Chloro-2-iodophenyl)(1,4-dihydro-1,4-epiminonaphthalen-9-yl)methanone (1e): light yellow oil, 752 mg, 77 %; ¹H NMR (400 MHz, CDCl₃) δ: 7.88 (s, 1H), 7.41–7.33 (m, 2H), 7.22–7.11 (m, 2H), 7.07 (d, J = 8.1 Hz, 1H), 7.04–6.97 (m, 3H), 6.09 (s, 1H), 5.09 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 163.2, 147.8, 147.6, 143.7, 142.6, 139.3, 139.2, 135.8, 128.5, 128.4, 125.4, 125.3, 121.6, 120.6, 92.4, 66.8, 63.1; HRMS (ESI): m/z calcd for C₁₇H₁₁ClINO [M+H]⁺ 407.9652, found 407.9650.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(4-fluoro-2-iodophenyl)methanone (1f): light yellow solid, 601 mg, 64 %; m.p. 112–114 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.46 (dd, J = 8.1, 2.3 Hz, 1H), 7.24 (d, 7.0 Hz, 1H), 7.07–6.92 (m, 4H), 6.91–6.81 (m, 3H), 5.95 (s, 1H), 4.95 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 162.4, 161.2 (d, J = 254.5 Hz), 146.7 (d, J = 20.1 Hz), 142.7, 141.5, 136.0 (d, J = 3.6 Hz), 127.9 (d, J = 8.5 Hz), 125.9, 125.7, 124.4, 124.2, 120.5 119.5, 114.4 (d, J = 21.5 Hz), 91.1 (d, J = 8.2 Hz), 65.8, 62.0; HRMS (ESI): m/z calcd for C₁₇H₁₁FINO [M+H]⁺ 391.9948, found 391.9942.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(2-iodo-4-(trifluoromethyl)phenyl)methanone (1g): light yellow solid, 751 mg, 71 %, m.p. 128–130 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.10 (s, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.38 (d, J = 6.6 Hz, 1H), 7.29–7.20 (m, 1H), 7.19– 7.10 (m, 2H), 7.03–6.98 (m, 3H), 6.10 (s, 1H), 5.05 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 162.6, 147.5 (d, J = 17.6 Hz), 144.4, 143.6, 142.6, 136.6 (q, J = 3.8 Hz), 132.7 (q, J = 33.1 Hz), 127.8, 125.5, 125.4, 125.2 (q, J = 3.6 Hz), 123.9, 121.6, 121.2, 120.7, 92.0, 66.6, 63.0; HRMS (ESI): m/z calcd for C₁₈H₁₁F₃INO [M+H]⁺ 441.9916, found 441.9909.

(5-Bromo-2-iodophenyl)(1,4-dihydro-1,4-epiminonaphthalen-9-yl)methanone (1h): light yellow solid, 714 mg, 66 %; m.p. 150–152 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.67 (d, J = 8.3 Hz, 1H), 7.35 (d, J = 7.1 Hz, 1H), 7.26–7.19 (m, 2H), 7.17 (d, J = 6.1 Hz, 1H), 7.11 (dd, J = 5.5, 2.4 Hz, 1H), 7.04–6.92 (m, 3H), 6.06 (s, 1H), 5.08 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.3, 147.7, 147.5, 143.6, 142.7, 142.6, 141.1, 133.9, 130.6, 125.5, 125.3, 122.6, 121.6, 120.7, 90.1, 66.7, 63.0; HRMS (ESI): m/z calcd for C₁₇H₁₁BrINO [M+H]⁺ 451.9147, found 451.9138.

(5-Chloro-2-iodophenyl)(1,4-dihydro-1,4-epiminonaphthalen-9-yl)methanone (1i): off white solid, 713 mg, 73 %; m.p. 128–130 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.78 (d, J = 8.3 Hz, 1H), 7.41–7.37 (d, J = 7.0 Hz, 1H), 7.23–7.18 (d, J = 7.0 Hz, 1H), 7.18–7.08 (m, 3H), 7.07–6.98 (m, 3H), 6.10 (s, 1H), 5.12 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 161.4, 146.6, 146.5, 142.6, 141.6, 141.3, 139.9, 133.7, 130.0, 126.7, 124.4, 124.3, 120.5, 119.7, 88.2, 65.6, 61.9; HRMS (ESI): m/z calcd for C₁₇H₁₁ClINO [M+H]⁺407.9652, found 407.9647.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(5-fluoro-2-iodophenyl)methanone (1j): off white solid, 535 mg, 57 %; m.p. 152–153 °C; ¹H NMR (400 MHz, CDCl3) δ : 7.82 (dd, J = 9.2, 5.3 Hz, 1H), 7.39 (d, J = 6.3 Hz, 1H), 7.21 (d, J = 6.3 Hz, 1H), 7.16 (dd, J = 5.6, 2.5 Hz, 1H), 7.08–6.97 (m, 3H), 6.94–6.84 (m, 2H), 6.11 (s, 1H), 5.11 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.6 (d, J = 250.3 Hz), 162.5, 147.7, 147.5, 143.6, 142.6, 142.5 (d, J = 6.3 Hz), 141.3 (d, J = 7.6 Hz), 125.5, 125.3, 121.6, 120.7, 118.5 (d, J = 21.7 Hz), 115.3 (d, J = 23.5 Hz), 85.2 (d, J = 3.5 Hz), 66.6, 63.0; HRMS (ESI): m/z calcd for C₁₇H₁₁FINO [M+H]⁺ 391.9948, found 391.9940. (1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(2-iodo-5-methylphenyl)methanone (1k): white solid, 697 mg, 75 %; m.p. 172–174 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.63 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 6.3 Hz, 1H), 7.09 (d, J = 6.4 Hz, 1H), 7.06 (dd, J = 5.6, 2.5 Hz, 1H), 6.98–6.89 (m, 3H), 6.89–6.81 (m, 2H), 6.02 (s, 1H), 5.03 (s, 1H), 2.21 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 164.1, 147.9, 147.9, 143.7, 142.8, 140.7, 139.4, 138.4, 131.9, 128.4, 125.3, 125.2, 121.5, 120.6, 87.9, 66.7, 62.9, 20.9; HRMS (ESI): m/z calcd for C₁₈H₁₄INO [M+H]⁺ 388.0198, found 388.0196.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(2-iodo-5-methoxyphenyl)methanone (11): white solid, 667 mg, 69 %; m.p.139–140 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.71 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 6.6 Hz, 1H), 7.19 (d, J = 6.5 Hz, 1H), 7.15 (dd, J = 5.6, 2.5 Hz, 1H), 7.06–6.94 (m, 3H), 6.75–6.67 (m, 2H), 6.11 (s, 1H), 5.13 (s, 1H), 3.77 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.5, 158.7, 146.8, 146.7, 142.5, 141.7, 140.5, 139.4, 124.3, 124.2, 120.5, 119.6, 116.4, 112.2, 79.4, 65.6, 61.9, 54.5; HRMS (ESI): m/z calcd for C₁₈H₁₄INO₂ [M+H]⁺404.0147, found 404.0145.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(2-iodo-4,5-dimethoxyphenyl)methanone (1m): white solid, 655 mg, 63 %; m.p. 172–175 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.38 (d, J = 6.7 Hz, 1H), 7.24 (s, 1H), 7.19 (d, J = 6.6 Hz, 1H), 7.15 (dd, J = 5.5, 2.3 Hz, 1H), 7.04–6.97 (m, 3H), 6.65 (s, 1H), 6.08 (s, 1H), 5.15 (s, 1H), 3.91 (s, 3H), 3.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ: 164.2, 150.2, 149.2, 148.0, 147.9, 143.6, 142.7, 133.1, 125.3, 125.2, 121.8, 121.5, 120.5, 110.8, 80.8, 67.0, 63.1, 56.3, 56.1; HRMS (ESI): m/z calcd for C₁₉H₁₆INO₃ [M+H]⁺ 434.0253, found 434.0252.

(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)(5-iodobenzo[d][1,3]dioxol-4-yl)methanone (1n): white solid, 711 mg, 71 %; m.p. 193– 195 °C; ¹H NMR (400 MHz, DMSO) δ: 7.40 (dd, J = 5.0, 2.8 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.28 (d, J = 5.0 Hz, 1H), 7.18 (dd, J = 5.5, 2.4 Hz, 1H), 7.09 (dd, J = 5.4, 2.4 Hz, 1H), 7.00–6.91 (m, 2H), 6.82 (d, J = 8.2 Hz, 1H), 5.99 (s, 3H), 5.33 (bs, 1H); ¹³C NMR (100 MHz, DMSO) δ: 149.0, 148.4, 148.3, 145.4, 144.3, 143.9, 132.6, 125.4, 125.3, 121.5, 121.1, 111.6, 102.6, 82.4, 66.3, 62.8; HRMS (ESI): m/z calcd for C₁₈H₁₂INO₃ [M+H]⁺ 417.9940, found 417.9935.

(5,8-Dihydro-5,8-epiminonaphtho[2,3-d][1,3]dioxol-10-yl)(5-iodobenzo[d][1,3]dioxol-4-yl)methanone (1o): white solid, 741 mg, 67 %; m.p. 194–196 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.31 (d, J = 8.1 Hz, 1H), 7.19–7.09 (m, 1H), 7.05 (s, 1H), 6.95 (s, 1H), 6.80 (s, 1H), 6.63 (d, J = 8.2 Hz, 1H), 6.05–5.91 (m, 5H), 5.14 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 158.2, 148.2, 145.3, 144.6, 144.6, 143.9, 143.3, 142.2, 141.9, 132.5, 121.9, 111.1, 104.9, 104.1, 102.2, 101.3, 81.0, 66.4, 62.8; HRMS (ESI): m/z calcd for C₁₉H₁₂INO₅ [M+H]⁺ 461.9838, found 461.9828.

(5,8-Dihydro-5,8-epiminonaphtho[2,3-*d*][1,3]dioxol-10-yl)(2-iodo-4,5-dimethoxyphenyl)methanone (1p): white solid, 836 mg, 73 %; m.p. 192–194 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.23 (s, 1H), 7.14 (dd, J = 5.5, 2.4 Hz, 1H), 6.99 (dd, J = 5.4, 2.3 Hz, 1H), 6.95 (s, 1H), 6.76 (s, 1H), 6.66 (s, 1H), 5.98 (s, 1H), 5.96 (d, J = 1.3 Hz, 1H), 5.90 (d, J = 1.4 Hz, 1H), 5.06 (s, 1H), 3.89 (s, 3H), 3.81 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.7, 149.2, 148.2, 143.6, 143.6, 142.9, 142.0, 141.3, 141.1, 132.0, 120.8, 109.8, 104.0, 103.1, 100.2, 79.9, 66.1, 62.1, 55.2, 55.1; HRMS (ESI): m/z calcd for C₂₀H₁₆INO₅ [M+H]⁺ 478.0151, found 478.0147.

(2-Chlorophenyl)(1,4-dihydro-1,4-epiminonaphthalen-9-yl)methanone (1q): brown oil, 526 mg, 78 %; ¹H NMR (400 MHz, CDCl₃) δ: 7.43–7.35 (m, J = 7.5, 4.6 Hz, 3H), 7.30 (t, J = 7.9 Hz, 1H), 7.24 (d, J = 7.3 Hz, 1H), 7.20–7.12 (m, 2H), 7.05–6.95 (m, 3H), 6.14 (s, 1H), 5.15 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 160.5, 146.7, 142.8, 141.7, 133.6, 130.0, 129.7, 128.9, 127.3, 125.9, 124.3, 124.2, 120.4, 119.4, 65.5, 61.9; HRMS (ESI): m/z calcd for C₁₇H₁₂CINO [M+H]⁺ 282.0686, found 282.0684.

(2-Bromophenyl)(1,4-dihydro-1,4-epiminonaphthalen-9-yl)methanone (1r): brown oil, 577 mg, 74 %; ¹H NMR (400 MHz, CDCl₃) δ: 7.59 (dd, J = 7.9, 1.0 Hz, 1H), 7.39–7.24 (m, 3H), 7.21–7.14 (m, 2H), 7.12 (dd, J = 5.6, 2.5 Hz, 1H), 7.04–6.91 (m, 3H), 6.11 (s, 1H), 5.12 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 162.3, 147.8, 143.7, 142.8, 136.9, 133.2, 130.9, 128.3, 127.5, 125.3, 125.2, 121.4, 120.5, 119.5, 66.6, 62.9; HRMS (ESI): m/z calcd for C₁₇H₁₂BrNO [M+H]⁺ 326.0181, found 326.0176.

1-(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)-2-(2-iodophenyl)ethanone (3a): white solid, 715 mg, 77 %; m.p. 159–161 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.84 (dd, J = 7.9, 0.8 Hz, 1H), 7.32 (d, J = 6.5 Hz, 1H), 7.24–7.15 (m, 2H), 7.13 (dd, J = 7.7, 1.4 Hz, 1H), 7.09 (dd, J = 5.6, 2.5 Hz, 1H), 7.03–6.90 (m, 4H), 5.97 (s, 1H), 5.61 (s, 1H), 3.83–3.56 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.3, 148.2, 147.9, 143.9, 142.5, 139.4, 137.6, 130.2, 128.7, 128.4, 125.3, 125.0, 121.4, 120.4, 101.1, 65.8, 63.5, 45.9; HRMS (ESI): m/z calcd for C₁₈H₁₄INO [M+H]⁺ 388.0198, found 388.0197.

1-(1,4-Dihydro-1,4-epiminonaphthalen-9-yl)-2-(2-iodo-5-methylphenyl)ethanone (3b): white solid, 674 mg, 70 %; m.p. 142–144 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.71 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 6.8 Hz, 1H), 7.14–7.05 (m, 2H), 7.02–6.91 (m, 3H), 6.86 (s, 1H), 6.81–6.71 (m, 1H), 5.97 (s, 1H), 5.57 (s, 1H), 3.71 (s, 2H), 2.15 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.4, 148.2, 148.0, 143.7, 142.5, 139.1, 138.4, 137.1, 131.0, 129.7, 125.2, 124.9, 121.4, 120.4, 96.9, 65.8, 63.5, 45.9, 20.8; HRMS (ESI): m/z calcd for C₁₉H₁₆INO [M+H]⁺ 402.0355, found 402.0354.

1-(1,4-dihydro-1,4-epiminonaphthalen-9-yl)-3-(2-iodophenyl)propan-1-one (5): brown oil, 683 mg, 71 %; ¹H NMR (400 MHz, CDCl₃) δ: 7.82 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 5.8 Hz, 1H), 7.26 – 7.18 (m, 3H), 7.11 – 7.04 (m, 1H), 7.02 – 6.94 (m, 2H), 6.94 – 6.84 (m, 2H), 5.93 (s, 1H), 5.61 (s, 1H), 3.13 – 2.81 (m, 2H), 2.60 – 2.45 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ: 167.8, 148.2, 147.9, 144.3, 143.5, 142.3, 139.5, 130.0, 128.6, 128.2, 125.3, 125.1, 121.4, 120.4, 100.1, 65.7, 63.3, 35.8, 34.1. HRMS (ESI): m/z calcd for C₁₉H₁₆INO [M+H]⁺ 402.0355, found 402.0352.

General procedure for synthesis of substrates 6a and 6b

Compounds **6a** and **6b** were synthesized according to the previous reported method.⁴

A mixture of dibromide (2.78 g, 10 mmol) and freshly distilled *N*-Boc 2-methylpyrrole (2.7 g, 15 mmol) in toluene (20 mL) was cooled to -78 °C. *n*-Butyllithium (1.6 M in hexane; 13.8 mL, 22 mmol) was added dropwise over a period of 1.5 h. The resulting bright orange solution was allowed to warm up to 25 °C over 3 h and then left for a further 17 h at 25 °C. The reaction mixture was then quenched with water and the phases were separated. The aqueous layer was extracted with EtOAc and the organic layers were combined, dried over Na₂SO₄ and concentrated to give brown oil. The resulting crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=20/1 v/v) to give 1-methyl-*N*-Boc intermediate (2.29 g, 76 %) as a yellow oil.

1-methyl-*N*-Boc intermediate (722 mg, 2.4 mmol) was dissolved in 10 mL DCM followed by the addition of Et₃N (0.4 mL) and heating to reflux. TMSI (0.4 mL, 2.6 mmol) was added dropwise over 5 min and the reaction was heated at reflux for an additional 15 minutes, after which time TLC analysis showed complete consumption of 1-methyl-*N*-Boc intermediate. The reaction mixture was cooled to 0 °C then MeOH (0.1 mL, 3 mmol) was added dropwise. After 10 minutes at 0 °C, o-iodobenzoyl chloride (1.0 g, 3.6 mmol) was added and the reaction was allowed to warm to room temperature. The reaction was stirred at room temperature for an additional hour. Water (10 mL) and DCM was added until all precipitates dissolved. The organic and aqueous phases were separated and the aqueous phase was extracted twice with DCM. The organic fractions were combined, dried over Na_2SO_4 and concentrated. The resulting crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=10/1 v/v) to give compound **6a** (0.61 g, 57 %) as a light yellow solid.

The substrate **6b** was prepared by the similar procedure to **6a**.

(2-Iodo-5-methylphenyl)(5-methyl-5,8-dihydro-5,8-epiminonaphtho[2,3-d][1,3]dioxol-10-yl)methanone (6a): light yellow solid, 610 mg, 57 %; m.p. 279–281 °C; ¹H NMR (400 MHz, DMSO) δ : 10.23 (s, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.52 (s, 1H), 7.47 (s, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 7.1 Hz, 1H), 7.07 (d, J = 7.4 Hz, 1H), 6.17 (s, 2H), 2.50 (s, 3H), 2.36 (s, 3H); ¹³C NMR (100 MHz, DMSO) δ : 168.9, 147.9, 147.7, 143.7, 139.2, 138.3, 132.1, 131.9, 131.4, 130.2, 129.3, 126.4, 125.2, 122.1, 101.9, 101.3, 100.8, 89.9, 20.8, 19.9; HRMS (ESI): m/z calcd for C₂₀H₁₆INO₃ [M+H]⁺ 446.0253, found 446.0249.

(5-Iodobenzo[*d*][1,3]dioxol-4-yl)(5-methyl-5,8-dihydro-5,8-epiminonaphtho[2,3-*d*][1,3]dioxol-10-yl)methanone (6b): off white solid, 730 mg, 64 %; m.p. decomposed at 236 °C; ¹H NMR (400 MHz, DMSO) δ :10.41 (s, 1H), 7.51 (s, 1H), 7.44–7.32 (m, 3H), 7.24 (d, J = 7.5 Hz, 1H), 6.87 (d, J = 8.1 Hz, 1H), 6.20 (s, 2H), 6.17 (s, 2H), 2.57 (s, 3H); ¹³C NMR (100 MHz, DMSO) δ : 163.9, 147.9, 147.5, 147.2, 145.1, 131.6, 131.6, 130.5, 129.7, 125.8, 124.8, 124.7, 121.4, 110.9, 102.2, 101.4, 100.9, 99.9, 82.8, 19.4; HRMS (ESI): m/z calcd for C₂₀H₁₄INO₅ [M+H]⁺ 475.9995, found 475.9994.

General procedure for synthesis of substrates 6c

A mixture of dibromide (2.78 g, 10 mmol) and freshly distilled *N*-Boc 3-methylpyrrole (2.7 g, 15 mmol) in toluene (20 mL) was cooled to -78 °C. n-Butyllithium (1.6 M in hexane; 13.8 mL, 22 mmol) was added dropwise over a period of 1.5 h. The resulting bright orange solution was allowed to warm up to 25 °C over 3 h and then left for a further 17 h at 25 °C. The reaction mixture was then quenched with water and the phases were separated. The aqueous layer was extracted with EtOAc and the organic layers were combined, dried over Na₂SO₄ and concentrated to give a brown oil. The resulting crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=10/1 v/v) to give 2-methyl-*N*-Boc intermediate (1.62 g, 63 %) as a pink solid.

2-methyl-*N*-Boc intermediate (722 mg, 2.4 mmol) was dissolved in 10 mL DCM followed by the addition of Et₃N (0.4 mL) and heating to reflux. TMSI (0.4 mL, 2.6 mmol) was added dropwise over 5 min and the reaction was heated at reflux for an additional 15 minutes, after which time TLC analysis showed complete consumption of 1-methyl-*N*-Boc intermediate. The reaction mixture was cooled to 0 °C then MeOH (0.1 mL, 3 mmol) was added dropwise. After 10 minutes at 0 °C, o-iodobenzoyl chloride (1.0 g, 3.6 mmol) was added and the reaction was allowed to warm to room temperature. The reaction was stirred at room temperature for an additional hour. Water (10 mL)

Page 13 of 18

The Journal of Organic Chemistry

and DCM was added until all precipitates dissolved. The organic and aqueous phases were separated and the aqueous phase was extracted twice with DCM. The organic fractions were combined, dried over Na_2SO_4 and concentrated. The resulting crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=10/1 v/v) to give compound **6c** (0.86 g, 57 %) as a light yellow solid.

(5-Iodobenzo[*d*][1,3]dioxol-4-yl)(6-methyl-5,8-dihydro-5,8-epiminonaphtho[2,3-*d*][1,3]dioxol-10-yl)methanone (6c): light yellow solid, 860 mg, 57 %; m.p.>300 °C; ¹H NMR (400 MHz, DMSO) δ :10.32 (s, 1H), 7.65 (d, J = 8.3 Hz, 1H), 7.53 (s, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.33 (s, 1H), 7.28 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.23 (s, 2H), 6.13 (s, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz, DMSO) δ : 163.9, 148.3, 148.3, 147.2, 145.8, 132.5, 131.9, 130.4, 129.8, 128.1, 127.4, 126.6, 125.3, 111.5, 104.1, 102.7, 101.7, 100.4, 83.0, 19.2; HRMS (ESI): m/z calcd for C₂₀H₁₄INO₅ [M+H]⁺ 475.9995, found 475.9992.

General procedure for synthesis of target compounds 2a to 2p, 4a, 4b, 7a and 7b

To a solution of **1a** (74.6 mg, 0.2 mmol) in DMF (2.5 ml), In (57.5 mg, 0.5 mmol) was added. The mixture was heated to 110 °C and stirred for 20 h. The mixture was poured into water and extracted with EtOAc. The organic fractions were combined, dried over Na_2SO_4 and concentrated. The resulting crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate=4/1 v/v) to give compound **2a** (41.5 mg, 84 %) as an off white solid.

The rest of substrates **2b** to **2p**, **4a**, **4b**, **7a** and **7b** were prepared by the similar procedure to **2a**. The known compounds **2a-2m** and **2o-2p** showed satisfactory spectroscopic data in agreement with those reported in the literature.^{6,7}

13,14-Cis-dihydrobenzo[*c*]**phenanthridin-6-one (2a)**: off white solid, 41.5 mg, 84 %; m.p. 173–174 °C (lit.173–175 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 8.08 (dd, J = 7.7, 1.1 Hz, 1H), 7.53 (td, J = 7.5, 1.4 Hz, 1H), 7.39 (td, J = 7.6, 1.0 Hz, 1H), 7.35 – 7.25 (m, 4H), 7.16 (d, J = 7.2 Hz, 1H), 6.58 (dd, J = 9.6, 2.7 Hz, 1H), 5.81 (d, J = 2.6 Hz, 1H), 5.79 (d, J = 2.7 Hz, 1H), 5.76 (s, 1H), 4.87 (d, J = 5.7 Hz, 1H), 3.89 (dt, J = 5.4, 2.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.1, 139.6, 133.0, 132.7, 131.9, 129.3, 128.6, 128.4, 128.0, 127.9, 127.7, 127.6, 127.3, 127.1, 127.1, 52.2, 38.7; HRMS (ESI): m/z calcd for C₁₇H₁₃NO [M+H]⁺ 248.1075, found 248.1074.

10-Chloro-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2b**): white solid, 32.5 mg, 58 %; m.p. 183–184 °C (lit.182–184 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 7.96 (d, J = 7.7 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.30–7.26 (m, 2H), 7.23–7.08 (m, 3H), 6.53 (dd, J = 9.5, 2.9 Hz, 1H), 5.55 (d, J = 9.5 Hz, 1H), 5.27 (s, 1H), 4.72 (d, J = 5.1 Hz, 1H), 4.23 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 163.9, 136.9, 133.6, 132.9, 132.8, 130.9, 129.9, 129.9, 128.6, 128.4, 128.4, 127.6, 127.4, 126.9, 126.9, 51.7, 36.7; HRMS (ESI): m/z calcd for C₁₇H₁₂ClNO [M+H]⁺ 282.0686, found 282.0680.

10-Fluoro-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2c**): white solid, 33.4 mg, 63 %; m.p. 179–180 °C (lit.178–180 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 7.96 (d, J = 7.8 Hz, 1H), 7.48–7.38 (m, 2H), 7.37–7.30 (m, 2H), 7.28 (d, J = 4.5 Hz, 3H), 7.24 (d, J = 7.5 Hz, 1H), 6.64 (dd, J = 9.6, 3.1 Hz, 1H), 5.69 (d, J = 9.5 Hz, 1H), 5.31 (s, 1H), 4.86 (d, J = 5.3 Hz, 1H), 4.26 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 163.9, 159.4 (d, J = 247.0 Hz), 132.7, 130.9, 129.8, 128.7 (d, J = 8.0 Hz), 128.4, 128.3, 127.6 (d, J = 8.6 Hz), 127.3, 127.3, 126.5 (d, J = 17.3 Hz), 123.9 (d, J = 3.3 Hz), 119.6 (d, J = 21.5 Hz), 51.8, 32.8, 32.7; HRMS (ESI): m/z calcd for C₁₇H₁₂FNO [M+H]⁺ 266.0981, found 266.0974.

10-Methyl-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2d)**: white solid, 31.8 mg, 61 %; m.p. 201–202 °C (lit.201–203 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 8.00 (d, J = 7.6 Hz, 1H), 7.46–7.16 (m, 6H), 6.62 (dd, J = 9.5, 3.1 Hz, 1H), 5.59 (d, J = 9.5 Hz, 1H), 5.30 (s, 1H), 4.77 (d, J = 5.2 Hz, 1H), 4.03 (s, 1H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.3, 137.6, 135.0, 134.7, 132.8, 131.6, 129.7, 128.4, 128.3, 128.0, 127.7, 127.5, 127.3, 126.2, 51.9, 35.9, 18.9; HRMS (ESI): m/z calcd for C₁₈H₁₅NO [M+H]⁺ 262.1232, found 262.1229.

9-Chloro-13,14-cis-dihydrobenzo[c]phenanthridin-6-one (2e): white solid, 47.2 mg, 84 %; m.p. 203–204 °C (lit.202–204 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 8.06 (d, J = 8.3 Hz, 1H), 7.44–7.28 (m, 5H), 7.21 (d, J = 7.3 Hz, 1H), 6.65 (dd, J = 9.6, 2.5 Hz, 1H), 5.84 (dd, J = 9.6, 2.8 Hz, 1H), 5.59 (s, 1H), 4.90 (d, J = 5.5 Hz, 1H), 4.02–3.81 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 164.3, 141.4, 139.0, 132.5, 131.9, 129.7, 129.4, 128.6, 128.1, 127.9, 127.6, 127.4, 127.3, 127.2, 126.6, 52.2, 38.4; HRMS (ESI): m/z calcd for C₁₇H₁₂CINO [M+H]⁺ 282.0686, found 282.0675.

9-Fluoro-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2f**): white solid, 42.9 mg, 81 %; m.p. 176–179 °C (lit.176–178 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 8.11 (dd, J = 8.5, 5.9 Hz, 1H), 7.38–7.26 (m, 3H), 7.19 (d, J = 7.2 Hz, 1H), 7.08 (td, J = 8.5, 2.2 Hz, 1H), 7.03 (d, J = 8.9 Hz, 1H), 6.65 (dd, J = 9.5, 2.0 Hz, 1H), 5.94 (s, 1H), 5.86 (dd, J = 9.5, 3.1 Hz, 1H), 4.91 (d, J = 5.6 Hz, 1H), 3.91 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.6 (d, J = 249.9 Hz), 164.3, 142.5 (d, J = 8.4 Hz), 132.6, 132.0, 130.9 (d, J = 9.4 Hz), 129.3, 128.5, 127.9, 127.5, 127.4, 127.2, 124.5 (d, J = 2.7 Hz), 114.9 (d, J = 21.8 Hz), 113.9 (d, J = 22.2 Hz), 52.3, 38.6; HRMS (ESI): m/z calcd for C₁₇H₁₂FNO [M+H]⁺ 266.0981, found 266.0975.

9-(Trifluoromethyl)-13,14-cis-dihydrobenzo[c]phenanthridin-6-one (2g): white solid, 54.2 mg, 86 %; m.p. 210–212 °C (lit.211–213 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ: 8.19 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.58 (s, 1H), 7.38–7.26 (m, 3H), 7.18 (d, J = 7.2 Hz, 1H), 6.64 (dd, J = 9.6, 2.4 Hz, 1H), 6.03 (s, 1H), 5.84 (dd, J = 9.5, 3.0 Hz, 1H), 4.91 (d, J = 5.7 Hz, 1H), 4.10–3.78 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 163.8, 140.5, 134.6, 134.3, 132.5, 131.7, 131.2, 129.5, 128.7, 128.6, 128.1, 127.5, 127.3, 124.9, 124.6 (q, J = 3.5 Hz), 124.1 (q, J = 3.4 Hz), 122.2, 52.2, 38.5; HRMS (ESI): m/z calcd for C₁₈H₁₂F₃NO [M+H]⁺ 316.0949, found 316.0941.

8-Bromo-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2h**): white solid, 52.7 mg, 81 %; m.p. 242–244 °C (lit.243–245 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 8.24 (d, J = 2.0 Hz, 1H), 7.66 (dd, J = 8.1, 2.1 Hz, 1H), 7.41–7.32 (m, 1H), 7.30–7.27 (m, 2H), 7.21 (t, J = 8.4 Hz, 1H), 6.61 (dd, J = 9.6, 2.5 Hz, 1H), 5.78 (dd, J = 9.5, 2.8 Hz, 1H), 5.54 (s, 1H), 4.87 (d, J = 5.6 Hz, 1H), 3.89 – 3.86 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 162.6, 137.4, 134.9, 131.5, 130.6, 129.9, 128.7, 128.5, 127.9, 127.5, 126.8, 126.7, 126.5, 126.3, 120.6, 51.2, 37.2; HRMS (ESI): m/z calcd for C₁₇H₁₂BrNO [M+H]⁺ 326.0181, found 326.0175.

8-Chloro-13,14-cis-dihydrobenzo[*c*]phenanthridin-6-one (2i): white solid, 45.0 mg, 80 %; m.p. 219–220 °C (lit.219–221 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ: 8.06 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 8.1, 2.3 Hz, 1H), 7.38–7.30 (m, 1H), 7.28 (dd, J = 4.0, 1.7 Hz, 2H), 7.26 (s, 1H), 7.17 (d, J = 7.3 Hz, 1H), 6.60 (dd, J = 9.6, 2.6 Hz, 1H), 5.78 (dd, J = 9.6, 2.8 Hz, 1H), 5.72 (s, 1H), 4.86 (d, J = 5.7 Hz, 1H), 3.89 (dd, J = 5.5, 2.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 163.9, 137.9, 133.8, 133.0, 132.6, 131.7, 129.6, 129.5, 128.7, 128.6, 128.0, 127.9, 127.7, 127.5, 127.3, 52.2, 38.2; HRMS (ESI): m/z calcd forC₁₇H₁₂CINO [M+H]⁺ 282.0686, found 282.0684.

8-Fluoro-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2j**): white solid, 44.0 mg, 83 %; m.p. 223–225 °C (lit.222–225 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ: 7.77 (dd, J = 9.0, 2.8 Hz, 1H), 7.39–7.27 (m, 4H), 7.23 (td, J = 8.3, 2.8 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 6.59 (dd, J = 9.6, 2.6 Hz, 1H), 5.77 (dd, J = 9.5, 2.6 Hz, 1H), 5.70 (s, 1H), 4.86 (d, J = 5.7 Hz, 1H), 4.03 – 3.74 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 163.9 (d, J = 2.1 Hz), 162.2 (d, J = 246.6 Hz), 135.3 (d, J = 3.2 Hz), 132.6, 131.7, 130.0 (d, J = 7.5 Hz), 129.5, 128.9 (d, J = 7.5 Hz), 128.5, 128.3, 127.6, 127.5, 127.2, 120.1 (d, J = 22.0 Hz), 114.7 (d, J = 23.1 Hz), 52.4, 38.1; HRMS (ESI): m/z calcd for C₁₇H₁₂FNO [M+H]⁺ 266.0981, found 266.0975.

8-Methyl-13,14-cis-dihydrobenzo[c]phenanthridin-6-one (2k): white solid, 43.8 mg, 84 %; m.p. 196–199 °C (lit.196–198 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 7.85 (s, 1H), 7.27 (ddd, J = 11.0, 7.5, 3.6 Hz, 2H), 7.21 (d, J = 5.2 Hz, 2H), 7.16 (d, J = 7.7 Hz, 1H), 7.11 (d, J = 7.3 Hz, 1H), 6.51 (dd, J = 9.6, 2.7 Hz, 1H), 5.72 (dd, J = 9.5, 2.5 Hz, 1H), 5.43 (s, 1H), 4.79 (d, J = 5.7 Hz, 1H), 3.96–3.62 (m, 1H), 2.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.3, 137.6, 136.6, 133.9, 132.8, 131.9, 129.4, 128.9, 128.4, 128.3, 127.7, 127.6, 127.1, 52.4, 38.4, 21.1; HRMS (ESI): m/z calcd for C₁₈H₁₅NO [M+H]⁺ 262.1232, found 262.1228.

8-Methoxy-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (21**): white solid, 48.2 mg, 87 %; m.p. 183–185 °C (lit.182–184 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 7.63 (d, J = 2.8 Hz, 1H), 7.38–7.32 (m, 1H), 7.30–7.28 (m, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 7.12 (dd, J = 8.4, 2.8 Hz, 1H), 6.59 (dd, J = 9.6, 2.7 Hz, 1H), 5.79 (dd, J = 9.5, 2.3 Hz, 1H), 5.51 (s, 1H), 4.87 (d, J = 5.7 Hz, 1H), 3.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 165.0, 159.2, 132.8, 131.9, 131.6, 129.4, 129.1, 128.9, 128.4, 128.3, 127.7, 127.1, 127.0, 120.7, 111.1, 55.6, 52.5, 38.1; HRMS (ESI): m/z calcd for C₁₈H₁₅NO₂ [M+H]⁺ 278.1181, found 278.1177.

8,9-Dimethoxy-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2m)**: white solid, 55.3 mg, 90 %; m.p. 238–240 °C (lit.238–241 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 7.91 (s, 1H), 7.44 (s, 1H), 7.32–7.26 (m, 2H), 7.21 (td, J = 7.5, 1.2 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H), 6.73 (s, 1H), 6.57 (dd, J = 9.6, 2.3 Hz, 1H), 5.77 (dd, J = 9.6, 3.3 Hz, 1H), 4.87 (d, J = 6.3 Hz, 1H), 3.95 (s, 3H), 3.82 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 167.3, 153.3, 147.5, 132.8, 131.3, 129.4, 128.5, 127.8, 127.1, 126.7, 126.0, 125.9, 117.1, 109.5, 108.1, 55.3, 55.2, 51.6, 36.1; HRMS (ESI): m/z calcd for C₁₉H₁₇NO₃ [M+H]⁺ 308.1287, found 308.1285.

7,8-Methylenedioxy-13,14-cis-dihydrobenzo[*c*]**phenanthridin-6-one (2n)**: white solid, 49.5 mg, 85 %; m.p. 236–238 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.38 – 7.31 (m, 1H), 7.29 (t, J = 1.8 Hz, 2H), 7.18 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 7.9 Hz, 1H), 6.78 (d, J = 8.1 Hz, 1H), 6.59 (dd, J = 9.6, 2.6 Hz, 1H), 6.15 (dd, J = 6.7, 1.1 Hz, 2H), 5.80 (dd, J = 9.5, 2.6 Hz, 1H), 5.63 (s, 1H), 4.82 (d, J = 5.4 Hz, 1H), 3.92–3.68 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 163.1, 148.3, 147.9, 132.9, 132.7, 131.9, 129.3, 129.2, 128.3, 127.5, 127.3, 127.1, 119.7, 111.9, 111.5, 102.5, 52.7, 38.7, 29.7; HRMS (ESI): m/z calcd for C₁₈H₁₃NO₃ [M+H]⁺ 292.0974, found 292.0972.

7,8-Methylenedioxy-13,14-cis-dihydrobenzodioxolebenzo[*c*]**phenanthridin-6-one (20**): white solid, 58.3 mg, 87 %; m.p. decomposed at 260 °C (lit. decomposed at 260 °C)⁷; ¹H NMR (400 MHz, CDCl₃) δ : 6.93 (d, J = 7.9 Hz, 1H), 6.79–6.73 (m, 2H), 6.66 (s, 1H), 6.44 (dd, J = 9.5, 2.5 Hz, 1H), 6.14 (dd, J = 8.4, 1.2 Hz, 2H), 5.98 (s, 2H), 5.69 (dd, J = 9.5, 2.6 Hz, 1H), 5.64 (s, 1H), 4.70 (d, J = 5.5 Hz, 1H), 3.76 (dt, J = 5.5, 2.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 163.2, 148.3, 148.0, 147.9, 147.2, 133.0, 127.4, 127.3, 127.1, 119.6, 111.8, 111.4, 108.3, 107.7, 102.6, 101.4, 52.8, 38.6, 29.7; HRMS (ESI): m/z calcd for C₁₉H₁₃NO₅ [M+Na]⁺ 358.0691, found 358.0689.

7,13-Cis-dihydro-1*H***-benzo[***d***]naphtho[1,2-***b***]azepin-2-one (4a): white solid, 43.8 mg, 84 %; m.p. 168–170 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.50–7.09 (m, 8H), 6.71 (dd, J = 9.5, 2.9 Hz, 1H), 6.02 (d, J = 8.6 Hz, 1H), 5.44 (s, 1H), 5.01 (t, J = 4.2 Hz, 1H), 4.24 (d, J = 15.3 Hz, 1H), 4.11 (s, 1H), 3.77 (d, J = 15.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ: 171.8, 137.9, 133.5, 132.5, 132.1, 131.6, 130.8, 130.2, 129.3, 128.2, 127.8, 127.7, 127.7, 127.4, 127.0, 53.5, 43.9, 42.5; HRMS (ESI): m/z calcd for C₁₈H₁₅NO [M+H]⁺ 262.1232, found 262.1227.**

5-Methyl-7,13-cis-dihydro-1*H*-benzo[*d*]naphtho[1,2-*b*]azepin-2-one (4b): white solid, 50.1 mg, 91 %; m.p. 149–151 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.42–7.35 (m, 1H), 7.29 (d, J = 8.4 Hz, 3H), 7.24 (d, J = 7.3 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 7.01 (s, 1H), 6.69 (dd, J = 9.5, 2.7 Hz, 1H), 6.00 (d, J = 9.4 Hz, 1H), 5.44 (s, 1H), 4.98 (t, J = 4.3 Hz, 1H), 4.20 (d, J = 15.2 Hz, 1H), 4.07 (s, 1H), 3.71 (d, J = 15.2 Hz, 1H), 2.35 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 170.9, 135.9, 133.7, 132.5, 131.5, 131.3, 130.4, 130.2, 129.0, 128.2, 127.5, 127.1, 126.7, 126.4, 125.9, 52.5, 42.4, 41.4, 19.8; HRMS (ESI): m/z calcd for C₁₉H₁₇NO [M+H]⁺ 276.1388, found 276.1384.

8,12-Dimethyl-13,14-cis-dihydrobenzodioxolebenzo[*c*]**phenanthridin-6-one (7a**): light yellow solid, 45.9 mg, 72 %; m.p. 232–234 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.89 (s, 1H), 7.33 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 6.86 (s, 1H), 6.78 (s, 1H), 5.98 (s, 1H), 5.53 (s, 1H), 5.47 (s, 1H), 4.69 (d, J = 5.4 Hz, 1H), 3.75 (s, 1H), 2.39 (s, 1H), 2.02 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 164.3, 147.2, 145.8, 136.3, 136.2, 132.7, 130.5, 128.2, 127.3, 126.6, 125.9, 125.4, 122.9, 107.3, 103.9, 100.3, 51.9, 37.3, 20.1, 18.3; HRMS (ESI): m/z calcd for C₂₀H₁₈NO₃ [M+H]⁺ 320.1287, found 320.1285.

7,8-Methylenedioxy-12-methyl-13,14-cis-dihydrobenzodioxolebenzo[c]phenanthridin-6-one (7b): light yellow solid, 44.0 mg, 63 %; m.p. 244–246 °C; ¹H NMR (400 MHz, CDCl₃) δ: 6.91 (d, J = 7.8 Hz, 1H), 6.86 (s, 1H), 6.78 (s, 1H), 6.72 (d, J = 7.9 Hz, 1H), 6.13 (d, J = 9.1 Hz, 1H), 5.99 (s, 1H), 5.48 (s, 1H), 4.65 (d, J = 5.3 Hz, 1H), 3.71 (s, 1H), 2.03 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 147.2, 146.8, 145.9, 132.6, 130.7, 128.2, 125.3, 123.1, 118.6, 110.7, 110.4, 107.2, 104.0, 101.5, 100.4, 52.2, 37.7, 28.7, 18.3; HRMS (ESI): m/z calcd for C₂₀H₁₆NO₅ [M+H]⁺ 350.1028, found 350.1024.

ASSOCIATED CONTENT

Supporting Information

X-ray crystallography data, NMR spectra, HRMS. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

**E-mail: chenke*7758@163.com

**E*-mail: xiaohuaxu@nankai.edu.cn

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

This work was financially supported by National Key Technology R&D program (grant No2011BAE06B05).

REFERENCES

- (1) (a) Ishikawa, T.; Ishii, H. *Heterocycles*, **1999**, *50*, 627–639. (b) Pelz, K. *Collect. Czech. Chem. Commun.*, **1968**, *33*, 1852–1872. (c) Krane,
 B. D.; Fagbule, M. O.; Shamma, M.; Gözler, B. *J. Nat. Prod.*, **1984**, *47*, 1–43.
- (2) (a) Grossman, E.; Meckel, A. H.; Isaacs, R. L.; Ferretti, G. A.; Sturzenberger, O. P.; Bollmer, B. W.; Moore, D. J.; Lijana, R. C.; Manhart, M. D. J. Periodontol., 1989, 60, 435–440. (b) Eun, J. P.; Koh, G. Y. Biochem. Biophys. Res. Commun., 2004, 317, 618–624. (c) Li, D. J.; Zhao, B. P.; Sim, S. P.; Li, T. K.; Liu, A.; Liu, L. F.; LaVoie, E. J. Bioorg. Med. Chem., 2003, 11, 521–528. (d) Rivaud, M.; Mendoza, A.; Sauvain, M.; Valentin, A.; Jullian, V. Bioorg. Med. Chem., 2012, 20, 4856–4861. (e) Grynkiewicz, G.; Chojecka-Koryn, E.; Gadzikowska, M.; Chodkowska, A.; Jagiełło-Wójtowicz, E. Eur. J. Med. Chem., 2001, 36, 951–960.
- (3) Recent synthetic studies aimed at benzo[c]phenanthridines, see: (a) Petrone, D. A.; Yoon, H.; Weinstabl, H.; Lautens, M. Angew. Chem. Int. Ed., 2014, 53, 7908–7912. (b) Jhang, Y Y.; Fan-Chiang, T T.; Huang, J M.; Hsieh, J C.; Org. Lett., 2016, 18, 1154–1157. (c) Blanchot, M.; Candito, D A.; Larnaud, F.; Lautens, M. Org. Lett., 2011, 13, 1486–1489; and references cited therein.
- (4) McManus, H. A.; Fleming, M. J.; Lautens, M. Angew. Chem. Int. Ed., 2007, 46, 433-436.
- (5) Fleming, M. J.; McManus, H. A.; Rudolph, A.; Chan, W. H.; Ruiz, J.; Dockendorff, C.; Lautens, M. Chem. Eur. J., 2008, 14, 2112–2124.
- (6) Lv, P.; Huang, K. L.; Xie, L. G.; Xu, X. H. Org. Biomol. Chem., 2011, 9, 3133–3135.
- (7) Guo, C.; Huang, K. L.; Wang, B.; Xie, L. G.; Xu, X. H. RSC Adv., 2013, 3, 17271–17280.
- (8) Huang, K. L.; Guo, C.; Cheng, L. J.; Xie, L. G.; Zhou, Q. L.; Xu, X. H.; Zhu, S. F. Adv. Synth. Catal., 2013, 355, 2833–2838.
- (9) Selected reviews, see: (a) Augé, J.; Lubin-Germain, N.; Uziel, J. Synthesis, 2007, 12, 1739–1764. (b) Ranu, B. C. Eur. J. Org. Chem., 2000, 13, 2347–2356. (c) Nair, V.; Ros, S.; Jayan, C. N.; Pillai, B. S. Tetrahedron, 2004, 60, 1959–1982.
- (10) (a) Lubin-Germain, N. Hallonet, A. Huguenot, F. Palmier, S. Uziel, J. and Auge, J. Org. Lett., 2007, 9, 3679–3682. (b) Lubin-Germain, N. Baltaze, J.-P. Coste, A. Hallonet, A. Laure'ano, H. Legrave, G. Uziel, J.and Auge, J. Org. Lett., 2008, 10, 725–728. (c) Auge', J. Lubin-Germain, N. and Seghrouchni, L. Tetrahedron Lett., 2003, 44, 819–821. (d) Ousmer, M. Boucard, V. Lubin-Germain, N. Uziel, J. and Augé, J. Eur. J. Org. Chem., 2006, 5, 1216–1221.
- (11) John, J.; Anas, S.; Sajisha, V. S.; Viji, S.; Radhakrishnan, K. V. Tetrahedron Lett., 2007, 48, 7225–7227.
- (12) John, J.; Adarsh, B.; Radhakrishnan, K.V. Tetrahedron, 2010, 66, 1383–1388.
- (13) Duan, J. P.; Cheng, C. H. Organometallics, 1995, 14, 1608–1618.
- (14) Liu, P.; Pan, Y. M.; Hua, K.; Huang, X. C.; Liang, Y. Tetrahedron, 2013, 69, 7925–7930.

ACS Paragon Plus Environment

- (15) Zhang, F. H.; Liu, Y.; Xie, L. G.; Xu, X. H. RSC Adv., 2014, 4, 17218–17221.
- (16) Gao, Y. Z.; Wang, X.; Sun, L. D.; Xie, L. G.; Xu, X. H. Org. Biomol. Chem., 2012, 10, 3991–3998.
- (17) Papoian, V.; Minehan, T. J. Org. Chem., 2008, 73, 7376–7379.
- (18) Lautens, M.; Fagnou, K.; Zunic, V. Org. Lett., 2002, 4, 3465-3468.
- (19) For more details, see CCDC number 1446358. This material is available free of charge via the Internet at http://www.ccdc.cam.ac.uk/.